Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Protein A—a 42-kDa chemical component found in the cell wall of staphylococcus aureus—finds wide application in biotechnological industry. This is mainly attributed to features such as its ability to bind all human IgG class immunoglobulins except IgG3.
The global protein A resin market is estimated to account for US$ 511.7 Mn in terms of value in 2020 and is expected to reach US$ 907.3 Mn by the end of 2027.
Global Protein A Resin Market: Drivers
Approval of monoclonal antibodies for the treatment of various diseases is expected to propel growth of the global protein A resin market over the forecast period. For instance, in December 2019, The World Health Organization (WHO) prequalified its first biosimilar medicine – trastuzumab –– a monoclonal antibody for the treatment of early stage breast cancer. On an average trastuzumab costs US$ 20,000. However, the biosimilar version of trastuzumab is generally 65% cheaper than the originator.
Moreover, emergence of chronic diseases is also expected to aid in growth of the global protein A resin market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.
Natural Protein A held dominant position in the global protein A resin market in 2019, accounting for 63.1% share in terms of value, followed by Recombinant Protein A, respectively.
Figure 1. Global Protein A Resin Market Share (%), by Value, by Product, 2019
Global Protein A Resin Market: Restraints
Rise in alternate methods for purification of monoclonal antibodies is expected to hinder growth of the global protein A resin market. Affinity chromatography, which utilizes protein A resin, is a conventional method for purification of monoclonal antibodies. However, cost and availability of protein A resin is very high to perform purification process. To reduce production costs, various companies prefer alternative methods such as membrane chromatography, mixed chromatography, and aqueous two-phase extractions (ATPS) for purification of monoclonal antibodies in large scales.
Moreover, high costs associated with protein A resin is also expected to hinder growth of the market. The cost of protein A resin is US$ 15,000 – US$ 16,000 per one litre. Large-scale manufacturers require protein A in large amounts for purification, which increases production costs of monoclonal antibodies.
Protein A Resin Market Report Coverage
||Market Size in 2019:
||US$ 474.0 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 907.3 Mn
- North America: U.S., Canada
- Latin America: Brazil, Argentina, Mexico, Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
- Middle East: GCC Countries, Israel, Rest of Middle East
- Africa: South Africa, North Africa, Central Africa
- By Product: Natural Protein A, Recombinant Protein A.
- By Matrix Type: Agarose-based, Glass or Silica Based, Organic Polymer Based.
- By Application: Immunoprecipitation (IP), Antibody Purification.
- By End User: Biopharmaceutical Manufacturers, Clinical Research Laboratories, Academic Institutes.
GE Healthcare, Thermo Fisher Scientific, Repligen, Tosoh Bioscience, EMD Millipore, Novasep, GenScript Biotech Corporation, Purolite Life Sciences, and Expedeon Ltd.
- Technological advancement
- Increasing approvals of monoclonal antibodies
|Restraints & Challenges:
- Rise in alternate methods for purification of monoclonal antibodies
Global Protein A Resin Market: Opportunities
Launch of new monoclonal antibodies is expected to offer lucrative growth opportunities for players in the global protein A resin market. For instance, in September 2019, Biocare Medical, LLC launched a new mouse monoclonal antibody, p16 INK4a, for in vitro diagnostic use in the qualitative identification of the p16 INK4a protein by immunohistochemistry in formalin-fixed paraffin-embedded human tissues.
Moreover, increasing investment for R&D in monoclonal antibodies and biologics manufacturing is also expected to aid in growth of the global protein A resin market. For instance, in February 2018, Ferring Pharmaceuticals announced to invest around US$ 30 million in the new Ferring Biotech Center in Saint-Prex, Switzerland, for R&D in monoclonal antibodies and biologics manufacturing.
The global protein A resin market was valued at US$ 474.0 Mn in 2019 and is forecast to reach a value of US$ 907.3 Mn by 2027 at a CAGR of 8.5% between 2020 and 2027.
Figure 2. Global Protein A Resin Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027
Market Trends/Key Takeaways
R&D in synthesis of proteins is expected to propel growth of the global protein A resin market over the forecast period. For instance, in May 2020, researchers from Massachusetts Institute of Technology reported developed a protocol to rapidly produce protein chains up to 164 amino acids long.
Major players in the global protein A resin market are focused on launch of new products to expand their product portfolio. For instance, in June 2018, Purolite Life Sciences, a provider of pharmaceutical applications, launched new-generation protein A agarose resin ‘Praesto Jetted A50’. This new resin is a combination of jetting technology and high performance protein A ligand.
Global Protein A Resin Market: Competitive Landscape
Major players operating in the global protein A resin market include, GE Healthcare, Thermo Fisher Scientific, Repligen, Tosoh Bioscience, EMD Millipore, Novasep, GenScript Biotech Corporation, Purolite Life Sciences, and Expedeon Ltd.
Global Protein A Resin Market: Key Developments
Major players in the global protein A resin market are focused on investment in expansion of manufacturing capabilities to enhance their market share. For instance, in September 2018, Purolite Life Sciences started a manufacturing facility in Llantrisant Business Park, Wales, capable of producing 100,000L of its Praesto range of agarose Protein A affinity resins.